The experiment was conducted during three growing seasons and two planting dates. The cultivation site is placed at the ITGC Setif characterized by a semi-arid environment. The objective of the study is the analysis of phenotypic variability of traits measured for 15 varieties of durum wheat, through the average effects, to decline the ways, characters and varieties could play in favour of performance under the constraining semi-arid conditions. The year effect indicates that given the difficulty of predicting the performance enabled by years, it then makes sense to go straight for this performance within genotypes. Analysis of the effect genotype highlights characters connected to performance and is the Setifis variety that lends itself well. For the effect of sowing date, it is that early sowing promotes a better expression of the characteristics compared to late sowing.

initial literature search identified 1815 papers; four met the eligibility criteria. Three were randomized clinical trials and one was a phase II single-arm prospective cohort study. MEKi investigated included: pimasertib, selumetinib, trametinib, and binimetinib. A total of 680 patients were included in these studies, of which 416 were treated with a MEKi alone. All patients were treated for recurrent LGSOC. Objective response rates (ORR) to MEKi ranged from 12.1 to 26% and median progression-free survival (PFS) ranged from 7.2 to 13 months. Conclusion While one study demonstrated significantly improved efficacy of a MEKi over physician-choice systemic therapy in the treatment of recurrent LGSC, another did not show significant benefit. Two additional studies did not compare MEKi to current traditional chemotherapy or hormonal therapies used in the management of LGSC, limiting their clinical relevance. Mutation profiles within the tumors may affect the ORR to various MEKi. Further prospective and randomized trials are needed to determine the efficacy of MEKi in treating LGSC.